Aditya Bardia, MD, Massachusetts General Hospital, Boston, MA, provides an overview of the updated results from the EMERALD study (NCT03778931). Updated safety data were consistent with previously reported results and updated progression-free survival results show statistically significant results in favor of elacestrant, both in all patients and in patients with an ESR1 mutation, highlighting its potential role as a therapeutic option for patients with ER+/HER2- metastatic breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть